Chief Medical Officer · Avalo Therapeutics, Inc. · Avalo Therapeutics, Inc. — Stock Option (Right to Buy)
Side
M
Value
—
Shares
5,992
Price
—
Executed
Mar 16, 2026
Disclosed
Mar 18, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Mar 16 executedMar 18, 2026 disclosed
AVTX · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Option exercise — administrative, little informational value
Relative size+1 / 25
No reported dollar value · 4.2% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Avalo Therapeutics, Inc. — Stock Option (Right to Buy)
Ticker
AVTX
Shares
5,992
Price per share
$0
Execution date (reported)
Mar 16, 2026
Owned after transaction
149.0K shares
Rule 10b5-1 plan
Yes, as checked by the filer
Days from execution to publication
2
What this establishes
Doyle Mittie filed this Form 4 reporting a option exercise of AVTX on Mar 16, 2026. It became public on Mar 18, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Medical Officer
Doyle Mittiecik:0001918845
Issuer
Avalo Therapeutics, Inc.cik:0001534120
Revision history · 0
No field has changed since this record was first ingested.
